Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios

British Journal of Dermatology

Volumn 168, Issue 3, 2013, Pages 674-676

  Puig, L ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

FEMALE; HUMAN; MALE; NOTE; PSORIASIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; PSORIASIS;

EID: 84880630357     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12023     Document Type: Letter

References (19)

1. Leonardi C, Sobell JM, Crowley JJ et al. Efficacy, safety, and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol 2012;167:658-67.
2. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606.
3. Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One 2012;7:e33486.
4. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011;164:1091-6.
5. Chastek B, Gandra SR, Fox KM, Watson C. Dose escalation of TNF-blocker therapy among patients with psoriasis in a large managed care plan. Poster 5010, American Academy of Dermatology 70th annual meeting. San Diego, CA, U. S. A. 16-20 March 2012.
6. J Am Acad Dermatol 2012;66(4 Suppl. 1):AB190.
7. Bonafede M, Fox KM, Gandra SR, Watson C. Dose escalation of TNF-blocker therapy among US managed care patients with psoriasis. Poster 5264, American Academy of Dermatology 70th annual meeting. San Diego, CA, U. S. A. 16-20 March 2012.
8. J Am Acad Dermatol 2012;66(4 Suppl. 1):AB190.
9. Leonardi C, Strober B, Gottlieb AB et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010;9:928-37.
10. Van Lümig PP, Lecluse LL, Driessen RJ et al. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol 2010;163:838-46.
11. Strober BE, Poulin Y, Kerdel FA et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an openlabel study. J Am Acad Dermatol 2011;64:671-81.
12. Gottlieb AB, Kalb RE, Blauvelt A et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicentre, openlabel study. J Am Acad Dermatol 2012;67:642-50.
13. Griffiths CE, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28.
14. Puig L. Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis. J Eur Acad Dermatol Venereol 2013;27:e257-60.
15. Downs AM. Switching between antitumour necrosis factor alpha biologic agents - is patient weight an important consideration? Br J Dermatol 2009;160:1123-4.
16. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011;25:1007-11.
17. Ormerod AD. Switching biologics for psoriasis. Br J Dermatol 2010;163:667-9.
18. Bhutani T, Koo J. Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series. J Dermatolog Treat 2011;22:75-8.
19. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Antiinfliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21.